Usefulness of laparoscope-assisted antrectomy for gastric carcinoids with hypergastrinemia
- PMID: 20583448
Usefulness of laparoscope-assisted antrectomy for gastric carcinoids with hypergastrinemia
Abstract
The mechanisms responsible for development of gastric carcinoid tumors (type I carcinoids) in type A atrophic gastritis are hyperplasia of enterochromaffin-like cells that are associated with hypergastrinemia, and tumorigenesis. Endoscopic resection and gastrectomy are applied as treatment modalities for gastric carcinoids associated with gastrin hypersecretion. However, since the underlying pathology is the hyperplasia of gastrin-secreting cells and over-production of gastrin in the antropyloric region, antrectomy seems a logical treatment modality. To date, we have performed laparoscopic-assisted anterectomies in 3 cases of type I gastric carcinoid. The lesions have regressed or disappeared in 2 cases, in which resections of the foci were not performed. Furthermore, no has been observed in the other case, in which laparoscopic resection was performed. A laparoscopic antrectomy for type I gastric carcinoid is a minimally invasive treatment relevant to the pathology of the disease, and it is also expected to produce regression or even spontaneous resolution of the tumor.
Similar articles
-
Gastric carcinoids in patients with hypergastrinemia.J Am Coll Surg. 2004 Oct;199(4):552-5. doi: 10.1016/j.jamcollsurg.2004.06.019. J Am Coll Surg. 2004. PMID: 15454137
-
Multiple gastric carcinoids associated with hypergastrinemia. A review of five cases with clinicopathological analysis and surgical strategies.Anticancer Res. 2005 Nov-Dec;25(6C):4417-22. Anticancer Res. 2005. PMID: 16334119
-
Antrectomy for multicentric, argyrophil gastric carcinoids: a preliminary report.Surgery. 1988 Dec;104(6):1046-53. Surgery. 1988. PMID: 3194832
-
Hypergastrinemia and gastric enterochromaffin-like cells.Am J Surg Pathol. 1995;19 Suppl 1:S8-19. Am J Surg Pathol. 1995. PMID: 7762739 Review.
-
Gastric carcinoid tumors: the biology and therapy of an enigmatic and controversial lesion.Am J Gastroenterol. 1995 Mar;90(3):338-52. Am J Gastroenterol. 1995. PMID: 7872269 Review.
Cited by
-
[Gastric neuroendocrine tumors. Endoscopic and surgical treatment].Chirurg. 2011 Jul;82(7):574-82. doi: 10.1007/s00104-011-2068-x. Chirurg. 2011. PMID: 21691871 Review. German.
-
Netazepide, a gastrin receptor antagonist, normalises tumour biomarkers and causes regression of type 1 gastric neuroendocrine tumours in a nonrandomised trial of patients with chronic atrophic gastritis.PLoS One. 2013 Oct 1;8(10):e76462. doi: 10.1371/journal.pone.0076462. eCollection 2013. PLoS One. 2013. PMID: 24098507 Free PMC article. Clinical Trial.
-
Response and relapse rates after treatment with long-acting somatostatin analogs in multifocal or recurrent type-1 gastric carcinoids: A systematic review and meta-analysis.United European Gastroenterol J. 2020 Mar;8(2):140-147. doi: 10.1177/2050640619890465. Epub 2019 Nov 22. United European Gastroenterol J. 2020. PMID: 32213066 Free PMC article.
-
Recurrent gastric neuroendocrine tumors treated with total gastrectomy.World J Gastroenterol. 2015 Dec 14;21(46):13195-200. doi: 10.3748/wjg.v21.i46.13195. World J Gastroenterol. 2015. PMID: 26675502 Free PMC article.
-
Current concepts on gastric carcinoid tumors.Gastroenterol Res Pract. 2012;2012:287825. doi: 10.1155/2012/287825. Epub 2012 Dec 17. Gastroenterol Res Pract. 2012. PMID: 23316222 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical